Preliminary evidence of effects of potassium chloride on a metabolomic path to diabetes and cardiovascular disease
Ranee Chatterjee, Clemontina A Davenport, Lydia Kwee, David D'Alessio, Laura P Svetkey, Pao-Hwa Lin, Cris A Slentz, Olga Ilkayeva, Johanna Johnson, David Edelman, Svati H Shah, Ranee Chatterjee, Clemontina A Davenport, Lydia Kwee, David D'Alessio, Laura P Svetkey, Pao-Hwa Lin, Cris A Slentz, Olga Ilkayeva, Johanna Johnson, David Edelman, Svati H Shah
Abstract
Introduction: Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors.
Objective: We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile.
Methods: In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data.
Results: Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11).
Conclusions: KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile.
Clinical trials registry: Clinicaltrials.gov identifier: NCT02236598; https://ichgcp.net/clinical-trials-registry/NCT02236598.
Keywords: Branched-chain amino acids; Cardiovascular disease risk; Metabolites; Potassium chloride; Potassium supplements; Prediabetes.
Conflict of interest statement
No authors have any conflicts of interest.
Source: PubMed